| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
96,118,000 |
| Market
Cap: |
1.54(B) |
| Last
Volume: |
115,349 |
Avg
Vol: |
115,032 |
| 52
Week Range: |
$9.64 - $17.22 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Avadel Pharmaceuticals is a biopharmaceutical company. Co.'s primary product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. Co.'s commercial products are: Akovaz, which is indicated for the treatment of hypotension occurring in the setting of anesthesia; Bloxiverz, which is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep®, which is for the treatment of hypotension occuring in the setting of anesthesia; and Nouress, which is a sterile injectable product for use in the hospital setting.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
2,000 |
28,000 |
370,500 |
| Total Buy Value |
$0 |
$29,000 |
$377,497 |
$1,422,084 |
| Total People Bought |
0 |
1 |
3 |
6 |
| Total Buy Transactions |
0 |
1 |
4 |
18 |
| Total Shares Sold |
0 |
75,000 |
103,975 |
103,975 |
| Total Sell Value |
$0 |
$1,089,750 |
$1,522,364 |
$1,522,364 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
2 |
2 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fildes Francis |
Director |
– • – |
2017-01-03 |
4/A |
D |
$0.00 |
$0 |
D/D |
(15,000) |
0 |
|
- |
|
| Broadfin Capital, Llc |
10% Owner |
– – • |
2017-01-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,394,464 |
|
- |
|
| Broadfin Capital, Llc |
10% Owner |
– – • |
2017-01-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(4,394,464) |
0 |
|
- |
|
| Gusky David P |
See Remarks |
• – – |
2017-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
2,000 |
|
- |
|
| Thompson Phillandas T. |
See Remarks |
• – – |
2017-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
58,000 |
58,000 |
|
- |
|
| Hatten Sandra L |
See Remarks |
• – – |
2017-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
33,000 |
33,000 |
|
- |
|
| Fildes Francis |
Director |
– • – |
2017-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Sullivan Stephen G. |
See Remarks |
• – – |
2017-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
| Davis Gregory J. |
See Remarks |
• – – |
2017-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Elrod Marcus W |
See Remarks |
• – – |
2017-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
3,400 |
|
- |
|
| Stapleton Craig R |
Director |
– • – |
2017-01-03 |
4 |
A |
$0.00 |
$0 |
I/I |
56,200 |
16,200 |
|
- |
|
| Stapleton Craig R |
Director |
– • – |
2017-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
492,678 |
492,678 |
|
- |
|
| Monteith David |
See Remarks |
• – – |
2017-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
32,500 |
32,500 |
|
- |
|
| Dsilva Dhiren |
See Remarks |
• – – |
2017-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Macke Scott A. |
See Remarks |
• – – |
2017-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
52,000 |
52,000 |
|
- |
|
| Kanan Michael F |
See Remarks |
• – – |
2017-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
18,000 |
|
- |
|
| Cerutti Guillaume |
Director |
– • – |
2017-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
| Anderson Michael S |
Chief Executive Officer |
• • – |
2017-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
223,250 |
223,250 |
|
- |
|
| Anderson Michael S |
Chief Executive Officer |
• • – |
2016-12-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(223,250) |
0 |
|
- |
|
| Davis Gregory J. |
See Remarks |
• – – |
2016-12-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(30,000) |
0 |
|
- |
|
| Hatten Sandra L |
See Remarks |
• – – |
2016-12-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(33,000) |
0 |
|
- |
|
| Macke Scott A. |
See Remarks |
• – – |
2016-12-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(52,000) |
0 |
|
- |
|
| Gusky David P |
See Remarks |
• – – |
2016-12-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,000) |
0 |
|
- |
|
| Sullivan Stephen G. |
See Remarks |
• – – |
2016-12-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(10,000) |
0 |
|
- |
|
| Thompson Phillandas T. |
See Remarks |
• – – |
2016-12-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(58,000) |
0 |
|
- |
|
190 Records found
|
|
Page 5 of 8 |
|
|
